MOODY’S-ANALYTICS
11.6.2019 11:02:08 CEST | Business Wire | Press release
Moody’s Analytics, a leading provider of financial intelligence, has announced that Greek digital bank, Praxia bank , has selected the Moody’s Analytics suite of regulatory solutions for asset liability management (ALM), IFRS 9, and Basel III compliance.
Praxia bank will use the Moody’s Analytics RiskFoundation™ platform to consolidate and centralize risk management data across its organization using one solution. The award-winning platform delivers a standardized single point of control for performing risk analysis and regulatory reporting tasks, enabling the bank to best utilize its IT investment and execute a consistent enterprise-wide risk management strategy.
Praxia bank will also use the award-winning Moody’s Analytics RiskConfidence™ solution for IFRS 9, and ALM and liquidity risk management. The integrated solution will allow the bank to efficiently cover ALM and liquidity risk.
For Basel III compliance , Praxia bank has selected the RiskAuthority™ software, a comprehensive solution covering data management, regulatory capital calculations, and supervising reporting requirements. Its embedded Basel III calculation ratios and automated workflow processes will enable the bank to deliver efficient and streamlined Basel III compliance while leveraging the automation the solution affords.
“Working with one technology vendor brings significant advantages from an implementation and operations perspective,” said Thanos Papanikolaou, Chief Risk Officer at Praxia bank. “In view of our launch in Greece, we have proudly selected Moody’s Analytics to be our strategic partner. Its platforms allow us to efficiently monitor and manage risk, as well as support the various – and evolving - compliance and regulatory guidelines.”
“As banks globally look for ways to extract value from their regulatory technology investment, there is increasing demand for solutions that enable financial institutions to create synergies between compliance and business optimization,” said Andy Frepp, General Manager at Moody’s Analytics. “We look forward to working with Praxia bank to provide regulatory technology that supports their vision while offering a leaner, more agile approach to risk management.”
Click here to learn more about the Moody’s Analytics suite of regulatory reporting solutions.
About Moody’s Analytics
Moody’s Analytics provides financial
intelligence and analytical tools to help business leaders make better,
faster decisions. Our deep risk expertise, expansive information
resources, and innovative application of technology help our clients
confidently navigate an evolving marketplace. We are known for our
industry-leading and award-winning solutions, made up of research, data,
software, and professional services, assembled to deliver a seamless
customer experience. We create confidence in thousands of organizations
worldwide, with our commitment to excellence, open mindset approach, and
focus on meeting customer needs. For more information about Moody’s
Analytics, visit our website
or connect with us on Twitter
or LinkedIn
.
Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.
About Praxia bank
Praxia bank was created in 2018 and is
expected to fully launch within 2019. Praxia bank is a privately-owned
bank with a solid international shareholder structure operating under
the supervision of the Bank of Greece. Deposits are protected by the
Hellenic Deposit & Investment Guarantee Fund. Praxia bank’s executive
team includes talented professionals who bring a wealth of local and
international banking experience and share a common vision: to offer a
sophisticated banking experience that is more humane and at the same
time more digital than ever, to meet the needs of small and medium-sized
businesses as well as retail customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005323/en/
Contact:
TRACEY SCOTT Moody’s Analytics Communications +44.207.772.5207 Moody’s Analytics Media Relations
moodysanalytics.com twitter.com/moodysanalytics linkedin.com/company/moodysanalytics
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom